A Phase I Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors

Trial Profile

A Phase I Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Dec 2015

At a glance

  • Drugs Eribulin (Primary) ; Irinotecan (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Dec 2015 Last checked against ClinicalTrials.gov record.
    • 21 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 22 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top